Home/Pipeline/Pancreatic Cancer Test

Pancreatic Cancer Test

Pancreatic Cancer

DevelopmentActive

Key Facts

Indication
Pancreatic Cancer
Phase
Development
Status
Active
Company

About Mosaique Diagnostic

Mosaique Diagnostic is a pioneer in clinical proteomics, leveraging its unique CE-MS platform to decode disease-specific peptide patterns from urine. Its core focus is the early, non-invasive detection and monitoring of chronic diseases, primarily in nephrology, oncology, and cardiology, enabling personalized medicine approaches. The company has commercialized several diagnostic tests in Germany through its subsidiary and maintains an extensive global academic and industry collaboration network. Its technology is backed by a robust publication record and a large proprietary database of human urinary proteome data.

View full company profile

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b
Electron IORTIntraop MedicalApproved